P-0234 - Analysis of Glasgow Prognostic Score(GPS) in KRAS Exon2 wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuxi...

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Colon Cancer
Rectal Cancer
Presenter Satoshi Yuki
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors S. Yuki1, T. Sasaki2, Y. Sakata3, Y. Kobayashi4, Y. Tsuji5, H. Naruse6, H. Okuda7, A. Hosokawa8, J. Konno9, K. Eto10, M. Kudo11, Y. Kawamoto12, N. Sonoda13, Y. Sato14, M. Uebayashi15, Y. Komatsu16, T. Kato17, K. Harada1, M. Onodera18, H. Fukushima19, T. Ohta20
  • 1Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo/JP
  • 2Department of Internal Medicine, Wakkanai City Hospital, Wakkanai/JP
  • 3CEO, Misawa City Hospital, Misawa/JP
  • 4Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro/JP
  • 5Department of Medical Oncology, Tonan Hospital, Sapporo/JP
  • 6Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate/JP
  • 7Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo/JP
  • 8Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Toyama/JP
  • 9Department of Internal Medicine, Hakodate Central General Hospital, Hakodate/JP
  • 10Department of Gastroenterology, Tomakomai City Hospital, Tomakomai/JP
  • 11Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo/JP
  • 12Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo/JP
  • 13Department of Internal Medicine, Tomakomai Nisshou Hospital, Tomakomai/JP
  • 14Department of Medical Oncology and Hematology, Sapporo Medical University, Sapporo/JP
  • 15Department of Gastroenterology, Japanese Red Cross Kitami Hospital, Kitami/JP
  • 16Hokkaido University Hospital, Sapporo/JP
  • 17Department of Internal Medicine, Hokkaido Gastroenterology Hospital, Sapporo/JP
  • 18Department of Gastroenterology, Abashiri Kosei General Hospital, Abashiri/JP
  • 19Department of Cancer Center, Hokkaido University Hospital, Sapporo/JP
  • 20Department of Gastroenterology, Sapporo Higashi Tokushukai Hospital, Sapporo/JP



The Glasgow Prognostic Score (GPS), combination of C-reactive protein and albumin, has reported its prognostic value in metastatic colorectal cancer patients receiving cytotoxic agents. However, in the salvage setting, the validity of GPS has not been reported in patients treated by cetuximab-based chemotherapy.


269 patients with mCRC treated by cetuximab contained chemotherapy were retrospectively registered from 27 centers in Japan (HGCSG 0901 study). Of these, the KRAS Exon2 wild type patients that were refractory to or intolerant for 5-FU/ irinotecan/ oxaliplatin, and were never administered anti-EGFR-antibody, were included in this analysis. Univariate and multivariate analysis for overall survival were performed using patient characteristics. Survival analyses were performed with Kaplan-Meier method, log-rank test and Cox proportional hazards model.


All data were available for prognostic categorization in 123 patients. Median survival was 9.9 months. The distribution and median survival for GPS were as follows: GPS 0 (n = 59; 13.1 months), GPS 1 (n = 32; 8.4 months), and GPS 2 (n = 32; 6.5 months). The survival difference was significant between GPS 0 and GPS 2 (p < 0.001), and between GPS 1 and GPS 2 (p = 0.032), but not between GPS 0 and GPS 1 (p = 0.065). In Cox multivariate analysis, GPS had shown an independent prognostic impact (GPS 0 vs 1: hazard ratio : 1.271, 95%CI : 0.803-2.012, p= 0.306, GPS 0 vs 2 : hazard ratio : 1.866, 95%CI : 1.131-3.079, p= 0.015).


It was shown that GPS might provide valuable information in salvage treatment with cetuximab-based regimen. Moreover, the prospective evaluation is needed for the further validation.